Rethinking Tuberculosis Treatment: Integrating Antimicrobial Compounds, Host Responses, and Comorbidities

Dear Colleagues,

Tuberculosis (TB) continues to pose a major global health challenge, underscored by the limited efficacy of current therapeutic regimens, the rapid emergence of drug-resistant Mycobacterium tuberculosis strains, and heterogeneous treatment outcomes across patient populations. The failure to effectively integrate antimicrobial drug discovery with host immune modulation, vaccine development, and disease-associated comorbidities has contributed to persistent gaps in TB control.

This Special Issue of Antibiotics focuses on recent advances in anti-tubercular antimicrobial compounds, resistance mechanisms, and therapeutic strategies that extend beyond conventional pathogen-centered approaches. Emphasis is placed on the development of novel drugs, optimization of existing antibiotics, and host-directed therapies that enhance treatment efficacy and shorten disease duration. In parallel, contributions addressing vaccine strategies, drug–vaccine interfaces, and the influence of TB-associated comorbidities such as diabetes and HIV are welcomed. By integrating mechanistic insights with translational perspectives, this Special Issue aims to highlight innovative and realistic therapeutic pathways for improved TB management in the era of antimicrobial resistance.

Dr. Ashok Aspatwar
Dr. Wenping Gong
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.